{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T15:30:37Z","timestamp":1744644637467},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,2]]},"DOI":"10.7759\/cureus.61539","type":"journal-article","created":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T19:03:13Z","timestamp":1717354993000},"source":"Crossref","is-referenced-by-count":1,"title":["Antiphospholipid Syndrome and Patent Foramen Ovale: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Maria","family":"Rocha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca A","family":"Correia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria In\u00eas","family":"Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Madureira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/art.42624","article-title":"The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"75","author":"Barbhaiya M","year":"2023","unstructured":"Barbhaiya M, Zuily S, Naden R, et al.. The 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023, 75:1687-702. 10.1002\/art.42624","journal-title":"Arthritis Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid Syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"13","author":"Jacobs L","year":"2024","unstructured":"Jacobs L, Wauters N, Lablad Y, Morelle J, Taghavi M. Diagnosis and management of catastrophic antiphospholipid Syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Antibodies (Basel). 2024, 13:21. 10.3390\/antib13010021","journal-title":"Antibodies (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00336","article-title":"Deep vein thrombosis and pulmonary embolism among patients with a cryptogenic stroke linked to patent foramen ovale-a review of the literature","volume":"11","author":"Zietz A","year":"2020","unstructured":"Zietz A, Sutter R, De Marchis GM. Deep vein thrombosis and pulmonary embolism among patients with a cryptogenic stroke linked to patent foramen ovale-a review of the literature. Front Neurol. 2020, 11:336. 10.3389\/fneur.2020.00336","journal-title":"Front Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10754","article-title":"Antiphospholipid antibodies are common in patients referred for percutaneous patent foramen ovale closure","volume":"61","author":"Dodge SM","year":"2004","unstructured":"Dodge SM, Hassell K, Anderson CA, Keller J, Groves B, Carroll JD. Antiphospholipid antibodies are common in patients referred for percutaneous patent foramen ovale closure. Catheter Cardiovasc Interv. 2004, 61:123-7. 10.1002\/ccd.10754","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6613-4","article-title":"Patent foramen ovale and atrial septal aneurysm can cause ischemic stroke in patients with antiphospholipid syndrome","volume":"260","author":"Tanaka Y","year":"2013","unstructured":"Tanaka Y, Ueno Y, Miyamoto N, Shimada Y, Tanaka R, Hattori N, Urabe T. Patent foramen ovale and atrial septal aneurysm can cause ischemic stroke in patients with antiphospholipid syndrome. J Neurol. 2013, 260:189-96. 10.1007\/s00415-012-6613-4","journal-title":"J Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead556","article-title":"What we know and what we don't know about catastrophic antiphospholipid syndrome","volume":"63","author":"Rodriguez-Pint\u00f3 I","year":"2024","unstructured":"Rodriguez-Pint\u00f3 I, Espinosa G, Cervera R. What we know and what we don't know about catastrophic antiphospholipid syndrome. Rheumatology (Oxford). 2024, 63:I46-53. 10.1093\/rheumatology\/kead556","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3 I","year":"2016","unstructured":"Rodr\u00edguez-Pint\u00f3 I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016, 15:1120-4. 10.1016\/j.autrev.2016.09.010","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2022.100039","article-title":"SCAI guidelines for the management of patent foramen ovale","volume":"1","author":"Kavinsky CJ","year":"2022","unstructured":"Kavinsky CJ, Szerlip M, Goldsweig AM, et al.. SCAI guidelines for the management of patent foramen ovale. JSCAI. 2022, 1:100039. 10.1016\/j.jscai.2022.100039","journal-title":"JSCAI"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1159\/000512184","article-title":"Patent foramen ovale closure among patients with hypercoagulable states maintained on antithrombotic therapy","volume":"146","author":"Buber J","year":"2021","unstructured":"Buber J, Guetta V, Orion D, Lubetsky A, Borik S, Vatury O, Israel A. Patent foramen ovale closure among patients with hypercoagulable states maintained on antithrombotic therapy. Cardiology. 2021, 146:375-83. 10.1159\/000512184","journal-title":"Cardiology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1693739","article-title":"Recurrence risk in patients with cryptogenic stroke, patent foramen ovale, and thrombophilia: a systematic review and meta-analysis","volume":"119","author":"Hviid CV","year":"2019","unstructured":"Hviid CV, Simonsen CZ, Hvas AM. Recurrence risk in patients with cryptogenic stroke, patent foramen ovale, and thrombophilia: a systematic review and meta-analysis. Thromb Haemost. 2019, 119:1839-48. 10.1055\/s-0039-1693739","journal-title":"Thromb Haemost"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/257955-antiphospholipid-syndrome-and-patent-foramen-ovale-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T19:03:19Z","timestamp":1717354999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/257955-antiphospholipid-syndrome-and-patent-foramen-ovale-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,2]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.61539","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,2]]}}}